Crossmark

Temporal changes in first-phase ejection fraction during evolution of heart failure with preserved ejection fraction and afterload-induced heart failure in mice

Crossref DOI link: https://doi.org/10.1007/s13105-026-01138-6

Published Online: 2026-02-04

Published Print: 2026-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gu, Haotian

Catibog, Norman

Zhao, Yue

Visnagri, Asjad

Chowienczyk, Philip J.

Shah, Ajay M.

Zhang, Min https://orcid.org/0000-0003-1657-1337
Funding

Funding for this research was provided by:

British Heart Foundation (RE/24/130035)

British Heart Foundation (CH/1999001/11735)

British Heart Foundation (PG/22/11055)
License Information

Text and Data Mining valid from 2026-02-04

Version of Record valid from 2026-02-04
More Information

Article History

Received: 18 June 2025

Accepted: 22 December 2025

First Online: 4 February 2026

Competing interests

: HG and PC are named on a patent of EF1. AMS is a Board advisor to Forcefield Therapeutics and Heqet Therapeutics.

Document is current

Any future updates will be listed below